ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
profitability factor · long-only model fund

Foundry CBOperProf Industry-Neutral Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FCBRHYPOTHETICAL MODEL
Since ’99
+355%
Expense Ratio
0.35%
placeholder
Holdings
213
cap-weighted
Inception
Dec 2020
placeholder
Full Sharpe
0.40
Ann. Return (LS)
7.0%
Ann. Volatility
17.5%
Max Drawdown
-50.2%
Test Sharpe ’19–26
0.42
Test FF5 α (ann.)
10.2%
vs Fama-French 5
Test FF5 α t-stat
1.72
not significant
Monthly turnover
15%
of the long leg, per rebalance
Cumulative return (LS)
355%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.69
what this fund holds
Long leg ann. return
13.3%
buyable, long-only
Long-short Sharpe
0.40
requires shorting
Bottom bucket ann. return
6.3%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

213 of 213 · 100.0% of book
TickerCompanySectorMarket capWeight
1NVDA
NVIDIA CORPTechnology$4.91T
25.08%
2AAPL
APPLE INCTechnology$4.90T
25.05%
3AMZN
AMAZON COM INCConsumer Cyclical$2.66T
13.59%
4META
META PLATFORMS INCCommunication Services$1.64T
8.38%
5MA
MASTERCARD INCFinancial Services$480.32B
2.45%
6LRCX
LAM RESEARCH CORPTechnology$391.80B
2.00%
7KO
COCA COLA COConsumer Defensive$350.91B
1.79%
8NFLX
NETFLIX INCCommunication Services$290.47B
1.48%
9KLAC
KLA CORPTechnology$277.91B
1.42%
10PEP
PEPSICO INCConsumer Defensive$187.15B
0.96%
11QCOM
QUALCOMM INCTechnology$181.06B
0.93%
12STX
SEAGATE TECHNOLOGY HOLDINGS PLCTechnology$176.62B
0.90%
13WDC
WESTERN DIGITAL CORPTechnology$164.49B
0.84%
14APP
APPLOVIN CORPTechnology$142.62B
0.73%
15SCCO
SOUTHERN COPPER CORPBasic Materials$142.48B
0.73%
16BKNG
BOOKING HOLDINGS INCIndustrials$140.78B
0.72%
17SYK
STRYKER CORPHealthcare$122.63B
0.63%
18ISRG
INTUITIVE SURGICAL INCHealthcare$122.33B
0.63%
19SBUX
STARBUCKS CORPConsumer Cyclical$120.23B
0.61%
20MDT
MEDTRONIC PLCHealthcare$106.50B
0.54%
21ADBE
ADOBE INCTechnology$94.31B
0.48%
22DDOG
DATADOG INCTechnology$92.08B
0.47%
23CDNS
CADENCE DESIGN SYSTEMS INCTechnology$91.05B
0.47%
24MMM
3M COIndustrials$83.37B
0.43%
25HCA
HCA HEALTHCARE INCHealthcare$82.34B
0.42%
26BSX
BOSTON SCIENTIFIC CORPHealthcare$65.44B
0.33%
27EA
ELECTRONIC ARTS INCCommunication Services$52.38B
0.27%
28ALAB
ASTERA LABS INCTechnology$52.04B
0.27%
29EW
EDWARDS LIFESCIENCES CORPHealthcare$49.36B
0.25%
30ADSK
AUTODESK INCTechnology$46.07B
0.24%
31MSCI
MSCI INCFinancial Services$45.77B
0.23%
32IDXX
IDEXX LABORATORIES INCHealthcare$44.76B
0.23%
33KDP
KEURIG DR PEPPER INCConsumer Defensive$42.05B
0.21%
34NTRA
NATERA INCHealthcare$38.87B
0.20%
35RBLX
ROBLOX CORPCommunication Services$37.02B
0.19%
36WDAY
WORKDAY INCTechnology$35.76B
0.18%
37ALNY
ALNYLAM PHARMACEUTICALS INCHealthcare$35.71B
0.18%
38RDDT
REDDIT INCCommunication Services$34.88B
0.18%
39ONC
BEONE MEDICINES LTDHealthcare$34.68B
0.18%
40UI
UBIQUITI INCTechnology$33.04B
0.17%
41DXCM
DEXCOM INCHealthcare$29.58B
0.15%
42FICO
FAIR ISAAC CORPTechnology$29.15B
0.15%
43RMD
RESMED INCHealthcare$28.86B
0.15%
44FTI
TECHNIPFMC PLCEnergy$28.73B
0.15%
45GEHC
GE HEALTHCARE TECHNOLOGIES INCHealthcare$28.69B
0.15%
46ILMN
ILLUMINA INCHealthcare$28.24B
0.14%
47OTIS
OTIS WORLDWIDE CORPIndustrials$28.18B
0.14%
48MTD
METTLER TOLEDO INTERNATIONAL INCHealthcare$26.47B
0.14%
49VRSK
VERISK ANALYTICS INCIndustrials$26.29B
0.13%
50VRSN
VERISIGN INCTechnology$25.27B
0.13%
51EXPD
EXPEDITORS INTERNATIONAL OF WASHINGTON INCIndustrials$23.91B
0.12%
52TEAM
ATLASSIAN CORPTechnology$23.67B
0.12%
53INCY
INCYTE CORPHealthcare$23.42B
0.12%
54STZ
CONSTELLATION BRANDS INCConsumer Defensive$22.69B
0.12%
55NBIX
NEUROCRINE BIOSCIENCES INCHealthcare$17.18B
0.09%
56LSCC
LATTICE SEMICONDUCTOR CORPTechnology$17.16B
0.09%
57THC
TENET HEALTHCARE CORPHealthcare$16.79B
0.09%
58NTNX
NUTANIX INCTechnology$14.89B
0.08%
59DECK
DECKERS OUTDOOR CORPConsumer Cyclical$14.79B
0.08%
60LOGI
LOGITECH INTERNATIONAL SATechnology$14.76B
0.08%
61EXEL
EXELIXIS INCHealthcare$14.06B
0.07%
62MLI
MUELLER INDUSTRIES INCIndustrials$13.08B
0.07%
63PINS
PINTEREST INCCommunication Services$13.00B
0.07%
64ALGN
ALIGN TECHNOLOGY INCHealthcare$12.66B
0.06%
65PEN
PENUMBRA INCHealthcare$12.52B
0.06%
66GDDY
GODADDY INCTechnology$12.49B
0.06%
67NYT
NEW YORK TIMES COConsumer Cyclical$12.29B
0.06%
68BF.B
BROWN FORMAN CORPConsumer Defensive$11.74B
0.06%
69HAS
HASBRO INCConsumer Cyclical$11.54B
0.06%
70HUBS
HUBSPOT INCTechnology$11.49B
0.06%
71PODD
INSULET CORPHealthcare$11.36B
0.06%
72CART
INSTACART (MAPLEBEAR INC)Consumer Cyclical$10.77B
0.06%
73DPZ
DOMINOS PIZZA INCConsumer Cyclical$10.72B
0.05%
74ARWR
ARROWHEAD PHARMACEUTICALS INCHealthcare$10.47B
0.05%
75GMED
GLOBUS MEDICAL INCHealthcare$10.45B
0.05%
76DOCU
DOCUSIGN INCTechnology$10.07B
0.05%
77CORT
CORCEPT THERAPEUTICS INCHealthcare$9.72B
0.05%
78MANH
MANHATTAN ASSOCIATES INCTechnology$9.66B
0.05%
79MTCH
MATCH GROUP INCCommunication Services$9.13B
0.05%
80ETSY
ETSY INCConsumer Cyclical$7.98B
0.04%
81TAP
MOLSON COORS BEVERAGE COConsumer Defensive$7.28B
0.04%
82SLAB
SILICON LABORATORIES INCTechnology$7.17B
0.04%
83DBX
DROPBOX INCTechnology$7.14B
0.04%
84CRUS
CIRRUS LOGIC INCTechnology$6.98B
0.04%
85SNDR
SCHNEIDER NATIONAL INCIndustrials$6.69B
0.03%
86MSA
MSA SAFETY INCIndustrials$6.60B
0.03%
87MXL
MAXLINEAR INCTechnology$6.43B
0.03%
88APPF
APPFOLIO INCTechnology$6.36B
0.03%
89DUOL
DUOLINGO INCTechnology$6.24B
0.03%
90TFX
TELEFLEX INCHealthcare$5.96B
0.03%
91SEZL
SEZZLE INCFinancial Services$5.87B
0.03%
92QLYS
QUALYS INCTechnology$5.61B
0.03%
93TXG
10X GENOMICS INCHealthcare$5.55B
0.03%
94PEGA
PEGASYSTEMS INCTechnology$5.39B
0.03%
95TVTX
TRAVERE THERAPEUTICS INCHealthcare$5.27B
0.03%
96RELY
REMITLY GLOBAL INCTechnology$5.08B
0.03%
97KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL PLCHealthcare$4.92B
0.03%
98MMED
MINIMED GROUP INCHealthcare$4.75B
0.02%
99LIVN
LIVANOVA PLCHealthcare$4.43B
0.02%
100VKTX
VIKING THERAPEUTICS INCHealthcare$4.31B
0.02%
101BOX
BOX INCTechnology$4.22B
0.02%
102CALM
CAL-MAINE FOODS INCConsumer Defensive$4.20B
0.02%
103COCO
VITA COCO COMPANY INCConsumer Defensive$4.18B
0.02%
104EXTR
EXTREME NETWORKS INCTechnology$3.97B
0.02%
105DOCS
DOXIMITY INCHealthcare$3.94B
0.02%
106QS
QUANTUMSCAPE CORPConsumer Cyclical$3.60B
0.02%
107NHC
NATIONAL HEALTHCARE CORPHealthcare$3.56B
0.02%
108HAE
HAEMONETICS CORPHealthcare$3.54B
0.02%
109RNG
RINGCENTRAL INCTechnology$3.46B
0.02%
110RCUS
ARCUS BIOSCIENCES INCHealthcare$3.44B
0.02%
111IDYA
IDEAYA BIOSCIENCES INCHealthcare$3.16B
0.02%
112CARG
CARGURUS INCConsumer Cyclical$3.16B
0.02%
113XNDU
XANADU QUANTUM TECHNOLOGIES LTDTechnology$2.98B
0.02%
114RARE
ULTRAGENYX PHARMACEUTICAL INCHealthcare$2.88B
0.01%
115ADEA
ADEIA INCTechnology$2.80B
0.01%
116AMBA
AMBARELLA INCTechnology$2.71B
0.01%
117GRND
GRINDR INCTechnology$2.71B
0.01%
118ALRM
ALARMCOM HOLDINGS INCTechnology$2.63B
0.01%
119TMDX
TRANSMEDICS GROUP INCHealthcare$2.56B
0.01%
120PTON
PELOTON INTERACTIVE INCConsumer Cyclical$2.55B
0.01%
121CALX
CALIX INCTechnology$2.50B
0.01%
122CMPR
CIMPRESS PLCCommunication Services$2.49B
0.01%
123NRIX
NURIX THERAPEUTICS INCHealthcare$2.40B
0.01%
124BCRX
BIOCRYST PHARMACEUTICALS INCHealthcare$2.36B
0.01%
125BHVN
BIOHAVEN LTDHealthcare$2.32B
0.01%
126LMAT
LEMAITRE VASCULAR INCHealthcare$2.32B
0.01%
127INTA
INTAPP INCTechnology$2.24B
0.01%
128HTFL
HEARTFLOW INCHealthcare$2.15B
0.01%
129AXGN
AXOGEN INCHealthcare$2.12B
0.01%
130CDNA
CAREDX INCHealthcare$2.05B
0.01%
131PLSE
PULSE BIOSCIENCES INCHealthcare$1.98B
0.01%
132HRMY
HARMONY BIOSCIENCES HOLDINGS INCHealthcare$1.96B
0.01%
133APPN
APPIAN CORPTechnology$1.92B
0.01%
134SAM
BOSTON BEER CO INCConsumer Defensive$1.86B
0.01%
135VRDN
VIRIDIAN THERAPEUTICS INCHealthcare$1.86B
0.01%
136NVCR
NOVOCURE LTDHealthcare$1.84B
0.01%
137SRPT
SAREPTA THERAPEUTICS INCHealthcare$1.82B
0.01%
138SONO
SONOS INCTechnology$1.80B
0.01%
139ASAN
ASANA INCTechnology$1.77B
0.01%
140ATRC
ATRICURE INCHealthcare$1.77B
0.01%
141DV
DOUBLEVERIFY HOLDINGS INCTechnology$1.75B
0.01%
142ANAB
ANAPTYSBIO INCHealthcare$1.69B
0.01%
143INSP
INSPIRE MEDICAL SYSTEMS INCHealthcare$1.46B
0.01%
144ARLO
ARLO TECHNOLOGIES INCBasic Materials$1.45B
0.01%
145YELP
YELP INCCommunication Services$1.44B
0.01%
146AIP
ARTERIS INCTechnology$1.43B
0.01%
147RMIX
SUNCRETE INCBasic Materials$1.40B
0.01%
148WINA
WINMARK CORPConsumer Cyclical$1.39B
0.01%
149REAL
THEREALREAL INCConsumer Cyclical$1.35B
0.01%
150NVAX
NOVAVAX INCHealthcare$1.35B
0.01%
151IRMD
IRADIMED CORPHealthcare$1.24B
0.01%
152LQDT
LIQUIDITY SERVICES INCConsumer Cyclical$1.23B
0.01%
153CBRL
CRACKER BARREL OLD COUNTRY STORE INCConsumer Cyclical$1.20B
0.01%
154HTLD
HEARTLAND EXPRESS INCIndustrials$1.19B
0.01%
155DRTS
ALPHA TAU MEDICAL LTDHealthcare$1.19B
0.01%
156TNDM
TANDEM DIABETES CARE INCHealthcare$1.17B
0.01%
157MGTX
MEIRAGTX HOLDINGS PLCHealthcare$1.15B
0.01%
158CRTO
CRITEO SACommunication Services$1.13B
0.01%
159UPWK
UPWORK INCIndustrials$1.12B
0.01%
160EYPT
EYEPOINT INCHealthcare$1.12B
0.01%
161BVS
BIOVENTUS INCHealthcare$1.01B
0.01%
162FBRX
FORTE BIOSCIENCES INCHealthcare$1.00B
0.01%
163VOR
VOR BIOPHARMA INCHealthcare$980M
0.01%
164ANNX
ANNEXON INCHealthcare$950M
0.00%
165EVER
EVERQUOTE INCCommunication Services$925M
0.00%
166TDUP
THREDUP INCConsumer Cyclical$852M
0.00%
167AVR
ANTERIS TECHNOLOGIES GLOBAL CORPHealthcare$823M
0.00%
168DSP
VIANT TECHNOLOGY INCTechnology$754M
0.00%
169WEST
WESTROCK COFFEE COConsumer Defensive$749M
0.00%
170AURA
AURA BIOSCIENCES INCHealthcare$723M
0.00%
171PHR
PHREESIA INCHealthcare$662M
0.00%
172TCMD
TACTILE SYSTEMS TECHNOLOGY INCHealthcare$648M
0.00%
173FAC
FACTORIAL ENERGY INCIndustrials$610M
0.00%
174NRDS
NERDWALLET INCCommunication Services$609M
0.00%
175FDMT
4D MOLECULAR THERAPEUTICS INCHealthcare$575M
0.00%
176OOMA
OOMA INCCommunication Services$568M
0.00%
177ANGO
ANGIODYNAMICS INCHealthcare$558M
0.00%
178NPCE
NEUROPACE INCHealthcare$548M
0.00%
179YEXT
YEXT INCTechnology$535M
0.00%
180RGNX
REGENXBIO INCHealthcare$511M
0.00%
181DCTH
DELCATH SYSTEMS INCHealthcare$442M
0.00%
182PBYI
PUMA BIOTECHNOLOGY INCHealthcare$434M
0.00%
183RLGT
RADIANT LOGISTICS INCIndustrials$431M
0.00%
184SGU
STAR GROUP LPEnergy$430M
0.00%
185CBIO
CRESCENT BIOPHARMA INCHealthcare$407M
0.00%
186STRO
SUTRO BIOPHARMA INCHealthcare$391M
0.00%
187CRNC
CERENCE INCTechnology$390M
0.00%
188NATR
NATURES SUNSHINE PRODUCTS INCConsumer Defensive$359M
0.00%
189XPER
XPERI INCTechnology$352M
0.00%
190ELMD
ELECTROMED INCHealthcare$349M
0.00%
191CV
CAPSOVISION INCHealthcare$335M
0.00%
192BKKT
BAKKT INCTechnology$323M
0.00%
193QTTB
Q32 BIO INCHealthcare$255M
0.00%
194ARTV
ARTIVA BIOTHERAPEUTICS INCHealthcare$241M
0.00%
195GLSI
GREENWICH LIFESCIENCES INCHealthcare$240M
0.00%
196SMTI
SANARA MEDTECH INCHealthcare$229M
0.00%
197SPOK
SPOK HOLDINGS INCHealthcare$222M
0.00%
198KPTI
KARYOPHARM THERAPEUTICS INCHealthcare$216M
0.00%
199AGEN
AGENUS INCHealthcare$209M
0.00%
200ANIK
ANIKA THERAPEUTICS INCHealthcare$203M
0.00%
201PDEX
PRO DEX INCHealthcare$183M
0.00%
202EGAN
EGAIN CORPTechnology$180M
0.00%
203INFU
INFUSYSTEM HOLDINGS INCHealthcare$180M
0.00%
204ARCT
ARCTURUS THERAPEUTICS HOLDINGS INCHealthcare$172M
0.00%
205VTVT
VTV THERAPEUTICS INCHealthcare$130M
0.00%
206CUE
CUE BIOPHARMA INCHealthcare$126M
0.00%
207INSG
INSEEGO CORPTechnology$122M
0.00%
208SOTK
SONO TEK CORPTechnology$86M
0.00%
209CSBR
CHAMPIONS ONCOLOGY INCHealthcare$85M
0.00%
210ATRA
ATARA BIOTHERAPEUTICS INCHealthcare$76M
0.00%
211BODI
BEACHBODY COMPANY INCCommunication Services$75M
0.00%
212BGSF
BGSF INCIndustrials$65M
0.00%
213XLO
XILIO THERAPEUTICS INCHealthcare$53M
0.00%

Full long-leg book as of July 2026 · cap-weighted · total market cap $19.57T. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

9 sectors
Technology
60.6%
Consumer Cyclical
14.6%
Communication Services
10.7%
Healthcare
5.6%
Consumer Defensive
3.2%
Financial Services
2.7%
Industrials
1.7%
Basic Materials
0.7%
Energy
0.1%

Portfolio Style

Size × value map of the long-leg book

213 classified
Value
Blend
Growth
Large
Mid
Small
1%7
32%35
66%48
<1%8
<1%21
<1%34
<1%15
<1%14
<1%10

Share of long-leg capital by market cap × book-to-market, using terciles of the 3,283-name universe at July 2026. Rows: Large ≥ $5.2B, Small < $819M. Columns: Value ≥ 0.62, Growth < 0.34 B/M. The dot marks the capital-weighted centroid of the book — 100% toward Large, 83% toward Growth. Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt100% → Large
SmallLarge
Value ↔ growth tilt83% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 213 names now. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
2
Failed
3
Not tested
2
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

2 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.

    Required
    >= 75.0%
    Actual
    47.9%
    Margin
    -27.1%
  • No more than 25% of total assets may be invested in the securities of any one issuer.

    Required
    <= 25.0%
    Actual
    25.1%
    Margin
    -0.1%

    Close to the line. The engine flags this verdict as one a routine data rebuild could flip. Read it as borderline rather than settled — the margin beside it is the whole story.

  • The fund will not concentrate: no more than 25% of total assets in any one industry (excluding government securities and cash items).

    Required
    <= 25.0%
    Actual
    27.0%
    Margin
    -2.0%
Reported separately — arithmetically implied
  • At least 50% of total assets must sit in cash, government securities, other RICs, and other securities limited to 5% of assets and 10% of the issuer's voting securities per issuer.

    Required
    >= 50.0%
    Actual
    47.9%
    Margin
    -2.1%

    Arithmetically entailed by '40 Act 5(b)(1) diversification (75%/5% asset leg) — it cannot fail independently, so it is reported outside the tally rather than counted as a separate check.

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

1 verdict(s) sit within 1.0pp of their limit and can be flipped by a routine data rebuild; do not headline them, and always show the margin.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 213 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.3 (95% CI 0.9-1.4)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
12.4%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.29x
within
parametric
1.19x
within
cornish fisher
1.09x
within

The estimators agree, which is mild evidence the number isn’t an artefact of one method.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 2016
Before publication (pre-2016)
0.44
Sharpe · 6.5% p.a.
January 1999December 2016 · 216 mo
Since publication
0.37
Sharpe · 8.0% p.a.
January 2017July 2026 · 115 mo
Change in Sharpe−0.07Sharpe weakened since publication

Annual return moved the other way (+1.5pp), so Sharpe and return disagree here — the change is partly a shift in volatility rather than in return.

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
73%
19 of 26 3-year windows made money
Worst window
-0.63
Sharpe, January 2003 – December 2005
January 1999July 2026
Median Sharpe
0.30
Dispersion
0.50
Best window
1.51

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.28.6%8.4%
3 yearsp.a.25.9%12.2%
5 yearsp.a.14.6%13.7%
10 yearsp.a.17.1%6.2%
Since inceptionp.a.12.1%5.6%
Calendar years
YearLong legLong-short
20267 mo11.9%5.3%
202522.1%0.4%
202443.4%36.3%
202350.1%12.5%
2022-36.2%-5.4%
202123.3%21.7%
202035.5%2.0%
201922.7%-10.0%
20184.3%10.5%
201712.7%-9.0%
20169.9%-6.5%
201515.9%38.6%
201416.9%27.5%
201335.9%6.1%
201212.3%6.7%
20116.4%0.1%
201010.7%-9.8%
200957.3%4.4%
2008-38.7%14.3%
200711.4%0.3%
20069.1%-6.5%
20056.1%5.3%
200418.2%-8.8%
200339.0%-15.2%
2002-14.3%14.4%
2001-17.5%7.5%
2000-16.1%36.0%
199958.2%2.6%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FCBR
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.35% (placeholder)
Inception2020-12-23 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$19.57T

Methodology

The Foundry CBOperProf Industry-Neutral Factor ETF tracks a rules-based model that ranks liquid U.S. common stocks, industry-neutralized within Fama-French industries, each month by a CBOperProf signal and holds the top decile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.